Lipidor AB (publ) announced that the company's planned Phase III clinical trial with the drug candidate AKP02G2 for the treatment of psoriasis has been cleared to start by the Indian Medical Products Agency (DCGI). The main objective of the study is to compare the therapeutic efficacy of AKP02G2 against mild to moderate psoriasis with a market-leading product. The application to start the clinical study was submitted to the Indian Medical Products Agency in December.

After a meeting with the agency's Subject Expert Committee, the go-ahead to start the study has now been obtained. The main objective of the study is to compare the therapeutic efficacy of AKP02G2 in mild to moderate psoriasis with the market-leading product Enstilar, with the intention of providing a basis for market approval in Europe in the first stage. The Phase III study will include 294 patients and is to be conducted by Cliantha Research, a well-reputed CRO (Clinical Research Organisation) with extensive experience in dermatological research.

The clinical trial material in the study will be manufactured by Oy MedFiles Ltd. in Finland.